Sign Up Today and Learn More About Rubius Therapeutics Stock
Invest in or calculate the value of your shares in Rubius Therapeutics or other pre-IPO companies through EquityZen's platform.
Rubius Therapeutics Stock
Rubius is developing a new class of drugs, Red-Cell Therapeutics™,
About Rubius Therapeutics Stock
Founded
2013
Headquarters
Cambridge, MA, US
Total Funding
145M
Industries
Software, Artificial Intelligence, Data and Analytics
Rubius Therapeutics Press Mentions
Stay in the know about the latest news on Rubius Therapeutics
Boston-area startups are on pace to overtake NYC venture totals
TechCrunch • Aug 04, 2018
India may become next restricted market for U.S. cloud providers
TechCrunch • Aug 04, 2018
Investors in Rubius Therapeutics
Discover investors in Rubius Therapeutics stock and explore their portfolio companies
Rubius Therapeutics Management
Leadership team at Rubius Therapeutics
Senior Vice President, Corporate Development
Nathan Dowden
Co-Founder and Chief Innovation Officer
Avak Kahvejian
Join now and verify your accreditation status to gain access to:
- Rubius Therapeutics current valuation
- Rubius Therapeutics stock price
- Available deals in Rubius Therapeutics and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
How to invest in Rubius Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Rubius Therapeutics through EquityZen funds. These investments are made available by existing Rubius Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Rubius Therapeutics stock?
Shareholders can sell their Rubius Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
